Historically, regenerative healing that brings the body back to the same level of function as it had before injury or disease has been pursued as far back as the early 20th century.1 By the 1970’s, science was beginning to document observations that fetuses in early gestation experienced a healing process vastly different than what is experienced outside of the womb.2,3
Our current understanding of fetal healing suggests that a unique complex (HC-HA/PTX3) can help orchestrate an ideal environment to support regenerative healing.4,5 Specifically, the fetus’ superior management of the body’s inflammatory mechanisms leads to organized and efficient tissue repair.
Over the last 30 years, these unique properties have been shown to reside within the placental tissues themselves. If processed appropriately, allograft placental tissue retains these properties and applies them to unrelated hosts.6,7,8 This transplantation of biology into mature tissue suggests a means of disrupting the inflammatory scarring type of repair inherent to adult tissue, and drives a regenerative process of restorative repair.
The Umbilical Cord sustains life and acts as a protective buffer to three core vessels through which oxygenated, nutrient rich blood flows to the baby during pregnancy. Structurally, this thick connective tissue consists of consecutive Amniotic Membrane and Wharton’s Jelly layers and has been shown to be the richest source of transplantable fetal biology. The umbilical cord and the amniotic membrane share similar regenerative properties and are derived from the same inner cell mass of the embryo.
The Amniotic Membrane (AM) is the inner layer of the placenta which surrounds the baby during pregnancy. AM shares its cellular origin with the fetus, and together they grow in parallel throughout the pregnancy. The AM is the only tissue designed by nature specifically as a universal transplant, providing an immuno-privileged barrier between the mother’s immune system and the developing child. Without this barrier, the mother’s body would reject the baby as a foreign body.
*TissueTech Inc. has published conceptual research elucidating the underlying management of placental tissue, including umbilical cord and amniotic membrane. This breakthrough research suggests that the HC-HA/PTX3 Complex plays an important role in facilitating an ideal environment suitable to manage healing across a range of surgical and wound management applications. This is disclosed in TissueTech’s pending application to the FDA. Each surgeon must evaluate the appropriateness of the techniques based on his or her own medical training and expertise. Many variables including patient pathology, anatomy, and surgical techniques may influence procedural outcomes. While these clinical experiences are valid, the results are not necessarily typical, indicative or representative of all procedures in which TissueTech’s products are utilized.
1 The Star, Christchurch NZ Issue 8668 7 July 1906
2 Somasundaram K et al. J Pathol (1970) 100:81-86. [online]
3 Rowlatt U. Virchows Arch. (1979)381: 353-361. [online]
4 Adzick N et al. Ann Surg (1994) 220:10-18.
5 Ferguson M. Ulster Med J (1998) 67 Suppll 1: 37-40. [online]
6 Dua H et al. Surv Opthalmol (2004) 49: 51-77. [online]
7 Bouchard et al. Ocul Surf (2004) 2: 201-211. [online]
8 Tseng S et al. Ocul Surf (2004) 2:177-87. [online]